PLUS1
113.15
-0.23 (-0.2%)
-0.23 (-0.2%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Madrigal Pharmaceuticals Inc | MDGL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -2.64 | -2.28% | 113.38 | 111.02 | 116.9286 | 116.02 | 116.02 | 00:00:01 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 99.00 | 132.50 | 33.50 | 25.28% | 1 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,273 | 154,590 | $ 113.31 | $ 17,515,880 | 239,916 | 56.82 - 127.25 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:16:47 | 1 | $ 113.15 | USD |
Madrigal Pharmaceuticals Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.75B | 15.43M | 6.71M | $ - | $ - | -5.45 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Madrigal Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/01/2020 | 17:20 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 5/29/2020 | 16:53 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/29/2020 | 16:53 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 5/07/2020 | 08:51 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/07/2020 | 06:50 | GlobeNewswire Inc. | Madrigal Pharmaceuticals Reports 2020 First Quarter.. |
| 5/07/2020 | 06:09 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 4/29/2020 | 17:16 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MDGL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 127.25 | 127.25 | 110.37 | 118.00 | 162,645 | -13.87 | -10.9% |
| 1 Month | 82.30 | 127.25 | 80.98 | 110.07 | 243,347 | 31.08 | 37.76% |
| 3 Months | 81.54 | 127.25 | 56.82 | 86.20 | 239,427 | 31.84 | 39.05% |
| 6 Months | 112.52 | 127.25 | 56.82 | 88.93 | 214,159 | 0.86 | 0.76% |
| 1 Year | 92.32 | 127.25 | 56.82 | 91.56 | 189,598 | 21.06 | 22.81% |
| 3 Years | 15.39 | 325.98 | 13.0886 | 135.04 | 206,913 | 97.99 | 636.71% |
| 5 Years | 8.35 | 325.98 | 6.60 | 131.71 | 165,768 | 105.03 | 1,257.84% |
Madrigal Pharmaceuticals Description
| Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
